Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Markers in Male Reproductive Impairments Causing Miscarriages

By LabMedica International staff writers
Posted on 21 Feb 2019
Recurrent pregnancy loss, (RPL) affecting 1% to 2% of couples, is defined as ≥3 consecutive pregnancy losses before 20-week' gestation. More...
Women with RPL are routinely screened for etiological factors, but routine screening of male partners is not currently recommended.

Sperm DNA plays a critical role in placentation, so it is biologically plausible that impairments in male reproductive function could increase the risk of RPL. Recent studies suggest that male partners affected by RPL have impaired sperm quality with reduced total motility and morphology and increased sperm DNA damage.

A team of hospital based scientists collaborating with the Imperial College London (London, UK) enrolled 50 men who were partners of women with RPL and 63 men as controls. The controls were slightly younger that the test subjects and were mainly of Caucasian descent. All sperm samples were analyzed within the Department of Andrology, Hammersmith Hospital (London, UK). Sperm morphology was analyzed on Papanicolaou pre-stained slides with Kruger strict criteria.

Semen reactive oxygen species (ROS) were measured with a validated in-house chemiluminescent assay. Each sample was gently mixed immediately before taking luminometer readings. DNA fragmentation was measured with the validated Halosperm method. Morning blood samples were analyzed for serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, testosterone, and sex hormone–binding globulin.

The scientists reported that total sperm motility, progressive sperm motility, and normal morphology were all reduced in the RPL group versus controls. Mean ±SE morning serum testosterone (nmol/L) was 15% lower in RPL than in controls (controls, 19.0 ± 1.0; RPL, 16.0 ± 0.8). Mean ±SE serum estradiol (pmol/L) was 16% lower in RPL than in controls (controls, 103.1 ± 5.7; RPL, 86.5 ± 3.4). Serum luteinizing hormone and follicle-stimulating hormone were similar between groups. Mean ±SE ROS (relative light units (RLU)/sec/106 sperm) were 4-fold higher in RPL than in controls (controls, 2.0 ± 0.6; RPL, 9.1 ± 4.1). Mean ± SE sperm DNA fragmentation (%) was 2-fold higher in RPL than in controls (controls, 7.3 ± 1.0; RPL, 16.4 ± 1.5).

The authors concluded that the data suggested that male partners of women with RPL have impaired reproductive endocrine function, increased levels of semen ROS, and sperm DNA fragmentation. Routine reproductive assessment of the male partners may be beneficial in RPL. The study was published in the January 2019 issue of the journal Clinical Chemistry.

Related Links:
Imperial College London
Hammersmith Hospital


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.